Transgenic model for delay-type hypersensitivity (DTH) and use thereof
US9955676B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 11, 2015 |
| Grant date | May 1, 2018 |
| Priority date | — |
| Expiry date | Feb 11, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/44
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.